Results for seroprotezzjoni translation from Maltese to English

seroprotezzjoni
rate* %

seroprotezzjoni /
seroprotection /

rata ta’ seroprotezzjoni
seroprotection rate

rata ta 'seroprotezzjoni (%) *
seroprotection rate (%) *

sp= seroprotezzjoni sc= serokonverżjoni
sp= seroprotection sc= seroconversion

rata ta’ seroprotezzjoni (95% ci)
seroprotection rate (95% ci)

għar- razza rata ta ’ seroprotezzjoni
antibody

valence (livell ta’ seroprotezzjoni)
valence (seropro tection level)

is- seroprotezzjoni fit-tul wara doża booster mhijiex magħrufa.
long-term seroprotection following a booster-dose is not known.

is-seroprotezzjoni ġeneralment tinkiseb fi żmien minn 2 sa 3 ġimgħat.
seroprotection is generally obtained within 2 to 3 weeks.

rata ta’ seroprotezzjoni* rata ta’ serokonverżjoni** fattur ta’ serokonverżjoni
seroprotection rate* seroconversion rate** seroconversion factor***

f’ġurnata 180, ir-rata ta' seroprotezzjoni kienet ta’ 13%.
at day 180, the seroprotection rate was 13%.

ir-rati ta’ seroprotezzjoni f’xahar 6, 12 u 24 kienu kif ġej:
the seroprotection at month 6, 12 and 24 were as follows:

ir-rati ta’ seroprotezzjoni 6 xhur, 12 u 24 xahar wara t-tilqima kienu kif ġej:
the seroprotection rates 6, 12 and 24 months after vaccination were as follows:

tabella 2: rati ta’ seroprotezzjoni/serokonverżjoni xahar wara s-serje ta’ tilqim primarju
table 2: seroprotection/seroconversion rates one month after the primary vaccination series

ir-rati ta’ seroprotezzjoni 6 xhur, 12, 24 u 36 xahar wara l-ewwel doża kienu kif ġej:
the seroprotection rates 6, 12, 24 and 36 months after the first dose were as follows:

1 rata ta’ seroprotezzjoni (i.e. proporzjon ta’ individwi b’titre hi  1:40);
1seroprotection rate (i.e. proportion of subjects with hi titre  1:40);

ir- rata ta 'seroprotezzjoni għall- anti- hbs f’ dan iż- żmien kienet 93. 3%.
the seroprotection rate for anti-hbs at this time point was 93.3%.

ir-rata ta’ seroprotezzjoni kontra l-epatite b żdiedet għal 95.1% fi tlett xhur wara l-ewwel doża.
the seroprotection rate against hepatitis b increased to 95.1% by three months after the first dose.

1 rata ta’ seroprotezzjoni (i.e. proporzjon ta’ individwi b’titre ta’ hi  1:40);
1seroprotection rate (i.e. proportion of subjects with hi titre  1:40);